• <code id="kgams"><tr id="kgams"></tr></code>
    <abbr id="kgams"></abbr>
  • <abbr id="kgams"></abbr>
    Home
    Who We Are
    What We Do
    Corporate Responsibility
    News
    Careers
    Investors
    Patients and HCPS
    Contact us
    Careers | Investors | Patients and HCPS | Contact us
    Careers Investors Patients and HCPS Contact us
    Home / Company News / Gan & Lee Pharmaceuticals’ Oral GZR18 Tablet Completes First Dosing in Phase I Clinical Trial
    Gan & Lee Pharmaceuticals’ Oral GZR18 Tablet Completes First Dosing in Phase I Clinical Trial
    Date:2024-04-08

    Beijing, China, March 08, 2024 — Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", stock code: 603087.SH) announces today that the first subject has been dosed successfully in a Phase I clinical trial in China for its independently developed innovative oral peptide-class GLP-1 receptor agonist (GLP-1 RA) — GZR18 tablet, aimed at treating Type 2 Diabetes Mellitus (T2DM).


    The single-center, randomized, open-label Phase I clinical study conducted by Gan & Lee Pharmaceuticals aims to evaluate the relative bioavailability, pharmacokinetics, pharmacodynamics, safety, tolerability, and the impact of meal timing on the pharmacokinetics, pharmacodynamics, safety, and tolerability of the GZR18 tablet in healthy adult subjects in China. The trial plans to enroll 116 healthy adult participants.


    Diabetes, a metabolic disease characterized by abnormal glucose metabolism, is primarily due to impaired insulin production or response, leading to ineffective blood glucose maintenance. T2DM, the most common form, constitutes the vast majority of diabetes cases worldwide, with its onset linked to complex causes including genetic factors and poor lifestyle habits, such as lack of exercise and obesity.1 Glucagon-like peptide-1 (GLP-1) is a crucial hormone secreted by intestinal L cells, regulating insulin and glucagon secretion based on blood glucose levels to maintain glucose stability. GLP-1 RAs, developed in recent years, mimic the function of GLP-1 to activate GLP-1 receptors, controlling blood glucose levels. Beyond glucose regulation, GLP-1 RAs have shown clinical benefits, such as aiding weight control and improving non-alcoholic fatty liver disease, gradually becoming the preferred medication for diabetes treatment over traditional insulin therapies. Despite most GLP-1 RAs being injectable, oral GLP-1 RAs, favored for convenience and better patient experience, represent a new research direction in diabetes treatment.2


    In the development of oral GLP-1 RAs, challenges for peptide-class drugs include overcoming gastrointestinal structural and functional barriers, like proteolytic degradation and the gastrointestinal wall barrier. Scientists enhance absorption and bioavailability in the gastrointestinal tract by integrating absorption enhancers into peptide medications. GZR18 tablet employs an advanced oral delivery technique, enhancing drug absorption in the stomach and extending the drug's half-life by resisting gastric protease degradation, thereby improving the bioavailability of GZR18. Prior clinical studies of GZR18 injection for T2DM and obesity/overweight management in China and the USA have preliminarily validated its excellent safety and efficacy. This Phase I clinical trial of the GZR18 tablet in China marks the first-in-human clinical study of GZR18's oral formulation, aiming to expedite the development of GZR18 and potentially offer patients more convenient treatment options domestically.


    About GZR18

    GZR18, developed by Gan & Lee, is a GLP-1 receptor agonist intended for the treatment of T2DM in adults and for weight management in obese/overweight individuals. Preclinical data suggests that GZR18 has potential benefits in reducing blood glucose levels and weight. Some clinical studies have confirmed its efficacy in these areas, and it has a good safety profile. Currently, the global development of GZR18 has entered the Phase II clinical research stage.


    References:

    1.     Chin J Diabetes Mellitus, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

    2.     Zheng Li, et al., Research Progress of Oral Glucagon-Like Peptide-1 Receptor Agonists and Consideration of Non-clinical Evaluation. Chinese Pharmaceutical Affaris, 2023,(7):825-833. DOI:10.16153/j.1002-7777.2023.07.012


    About Gan & Lee


    Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin?), fast-acting lispro injection (Prandilin?), fast-acting aspart injection (Rapilin?), mixed protamine zinc lispro injection (25R) (Prandilin?25), aspart 30 injection (Rapilin?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin?30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine?).


    In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.




    Copyright ? 2021 Gan & Lee Pharmaceuticals. All Rights Reserved. 京ICP備10213074號(hào)-1 | 京公網(wǎng)安備 11011202003900號(hào)
    Our websites

    Subscribe

    I read, agree with and accept all of the Privacy Policy and Terms of Use of this website.
    主站蜘蛛池模板: 国产又粗又猛又黄又爽无遮挡| 成年人黄色大片大全| 国产午夜无码精品免费看 | 无码专区aaaaaa免费视频| 国产精品日韩欧美在线| 亚洲人成网站看在线播放| 黄网站色视频大全免费观看| 无人高清影视在线观看视频| 免费a级毛片出奶水| 2019中文字幕在线视频| 日韩在线视频不卡一区二区三区| 国产精品一区二区三区高清在线 | 2023天天操| 日本无吗免费一二区| 动漫人物差差差动漫网站| 99精品国产一区二区三区2021 | 国产高清在线视频伊甸园| 亚洲aⅴ男人的天堂在线观看| 67194在线看片| 日韩在线播放全免费| 午夜不卡久久精品无码免费| 91久久大香线蕉| 日本理论片午午伦夜理片2021 | 东京一本一道一二三区| 美女视频黄a视频全免费网站色 | 欧美人与动性行为视频| 国产一级淫片a视频免费观看| bt天堂在线www最新版资源在线| 欧美αv日韩αv另类综合| 国产h肉在线视频免费观看| 99精品国产成人a∨免费看| 最近免费中文字幕大全免费版视频| 国产91中文剧情在线观看| 中文字幕日产无码| 精品久久久久久久免费加勒比| 国产精品泄火熟女| 久久99亚洲网美利坚合众国| 漂亮华裔美眉跪着吃大洋全集| 国产情侣激情在线视频免费看| 久久久久久久岛国免费播放| 波多野吉衣AV无码|